Global Alzheimer’s Disease Therapeutics And Diagnostics Market Set To Grow To $20bn By 2022

26 July 2018
Pharma

Visiongain has launched a new pharma report Global Alzheimer’s Disease Therapeutics and Diagnostics Market : Leading Drugs, R&D Pipeline Drugs, Biomarkers, Leading Companies

Alzheimer’s Disease is reported to be the most common form of dementia in developed countries, with a prevalence of about 1% at the age of 65 and over 25% in people older than 85 years of age. Currently, advances in diagnostic technologies remain moderate and the Alzheimer’s Disease biomarker market is still in its infancy. It is expected that several diagnostic tools in the future will offer an accurate assessment of whether an individual has Alzheimer’s Disease, rather than one definitive diagnostic tool.

The lead analyst of the report commented the Alzheimer’s disease therapeutics market has been stagnant over the last few years, with many drugs failing late stage clinical trials. The overall AD market has experienced a slow growth in revenues due to the patent expiries of key drugs in major markets. There is a more positive outlook in the diagnostics market with advances in blood-based biomarkers, they are making a huge impact on clinical research of Alzheimer’s drug candidates. The Alzheimer’s Disease market will experience steady growth driven by the rising prevalence of AD and the entry of disease-modifying therapies (DMTs), including the passive immunotherapies, solanezumab, gantenerumab, and BACE inhibitors, verubecestat, which will have significant uptake in major markets”

Leading companies featured in the report include Pfizer, Eisai, Actavis, Lundbeck, Daiichi Sankyo, Novartis, TauRx, vTv Therapeutics, Eli Lilly, Amarantus Biosciences Holdings, Piramal Enterprises, GE Healthcare, Navidea, DiaGenic.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call on +44 (0) 207 336 6100

About visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports discussing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Visiongain Publishes Artificial Intelligence (AI) in Drug Discovery Market Report 2021-2031

Factors such as increasing data volumes for analysis, quick turnaround time for the discovery and development new drug, computing power, AI also helps in targeted manufacturing and others drive the market growth.

01 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever